SAR405: Selective ATP-Competitive Vps34 Inhibitor for Precision Autophagy Inhibition

Executive Summary: SAR405 is a highly potent and selective ATP-competitive inhibitor of Vps34, with a dissociation constant (Kd) of 1.5 nM and an IC₅₀ of 1 nM against human recombinant Vps34, demonstrating no inhibition of class I/II PI3Ks or mTOR up to 10 μM (SAR405 product page). It disrupts autophagy by blocking Vps34 kinase activity, leading to impaired late endosome-lysosome function and defective cathepsin D maturation (Park et al., 2023). SAR405 acts downstream of AMPK-ULK1 signaling, offering a unique tool to dissect autophagy regulation in energy stress models. The compound is DMSO-soluble (>10 mM), ethanol-soluble (with sonication), and stable below -20°C (A8883 kit). SAR405 synergizes with mTOR inhibitors in blocking autophagosome formation, supporting its application in cancer and neurodegenerative disease research (Vatalis, 2024).

Biological Rationale

Macroautophagy (autophagy) is a conserved catabolic process essential for cellular homeostasis, particularly during nutrient or energy stress (Park et al., 2023). Vps34, a class III phosphoinositide 3-kinase (PI3K), generates phosphatidylinositol 3-phosphate (PI3P), a lipid crucial for autophagosome formation and vesicle trafficking. Genetic and pharmacological blockade of Vps34 impairs autophagy, resulting in defective vesicle maturation and substrate degradation. Recent studies challenge the canonical AMPK-ULK1-centric view of autophagy induction, highlighting alternative regulatory checkpoints at the Vps34 step (Vatalis, 2024). SAR405 specifically targets this node, enabling researchers to parse the contribution of Vps34 activity to autophagosome biogenesis and downstream trafficking, independent of upstream energy sensors.

Mechanism of Action of SAR405

SAR405 is an ATP-competitive inhibitor that binds with high affinity to the ATP-binding cleft of Vps34. The Kd for human recombinant Vps34 is 1.5 nM, and the enzymatic IC₅₀ is 1 nM, reflecting exquisite potency (SAR405 technical sheet). SAR405 shows no measurable inhibition of class I or II PI3Ks or mTOR at concentrations up to 10 μM, confirming its selectivity. Upon binding, SAR405 blocks Vps34 kinase activity, leading to accumulation of swollen late endosome-lysosomes and impaired cathepsin D maturation. In cellular models (e.g., GFP-LC3 HeLa and H1299 cells), SAR405 prevents autophagosome formation and autophagy flux, confirming functional inhibition at the biochemical and cellular levels (Staurosporine, 2024). SAR405 acts downstream of AMPK and ULK1, directly inhibiting the core PI3K step in autophagy initiation, regardless of upstream AMPK status (Park et al., 2023).

Evidence & Benchmarks

• SAR405 inhibits human recombinant Vps34 with a Kd of 1.5 nM and IC₅₀ of 1 nM in ATP-competitive binding assays (product data).
• No inhibition of class I/II PI3Ks or mTOR was observed at concentrations ≤10 μM (A8883 kit).
• SAR405 blocks autophagosome formation and autophagy flux in GFP-LC3 HeLa and H1299 cells, as shown by microscopy and Western blot analyses (Park et al., 2023).
• Disrupts late endosome-lysosome function, causing swollen organelles and impaired cathepsin D maturation in cell-based assays (SAL003, 2024).
• Synergizes with mTOR inhibitors (e.g., everolimus and Torin1) to abolish autophagy induction, supporting dual-pathway blockade (Vatalis, 2024).
• SAR405’s effects are independent of AMPK activation status, clarifying its placement in the autophagy regulatory hierarchy (Park et al., 2023).

Applications, Limits & Misconceptions

SAR405 is used for probing Vps34 kinase signaling in cancer, neurodegenerative disorders, and general studies of autophagy and vesicle trafficking. It enables precise dissection of autophagy inhibition below the AMPK-ULK1 regulatory level, making it valuable for experiments where upstream kinase status is ambiguous or altered (Vatalis, 2024). SAR405 is also used in combination with mTOR inhibitors to interrogate the interplay between mTORC1 and PI3K class III pathways. However, researchers should be aware of its limits and potential misconceptions:

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I/II PI3Ks or mTOR, thus it cannot be used as a pan-PI3K or mTOR pathway inhibitor (SAR405).
• It blocks autophagy at the autophagosome nucleation step, not at upstream energy-sensing events (e.g., AMPK activation) (Park et al., 2023).
• SAR405 is insoluble in water and must be dissolved in DMSO (≥10 mM) or ethanol (with sonication); improper preparation affects activity (A8883 kit).
• Long-term storage of solutions at ambient temperature or repeated freeze-thaw cycles can degrade SAR405 potency (product storage instructions).
• Interpretation of results must consider that SAR405 blocks autophagy regardless of AMPK status; thus, it is not suitable for studying upstream kinase regulation (Park et al., 2023).

This article extends the mechanistic insights discussed in "SAR405 and the New Paradigm in Autophagy Research" by integrating updated knowledge on AMPK-ULK1 pathway decoupling, and clarifies the scope of SAR405 relative to "SAR405: Selective Vps34 Inhibitor for Precision Autophagy" by focusing on quantitative benchmarks and workflow deployment.

Workflow Integration & Parameters

SAR405 should be prepared as a stock solution in DMSO (>10 mM) or ethanol (with ultrasonic assistance) and stored below -20°C for up to several months (A8883 kit). Working solutions must be freshly diluted into cell culture media, ensuring DMSO final concentration does not exceed 0.1% v/v. SAR405 is typically used at 10–100 nM for cellular assays, with higher concentrations (up to 1 μM) for acute inhibition studies. Controls lacking SAR405 or using inactive analogs are essential for specificity validation. SAR405 is compatible with fluorescence microscopy, Western blot, and vesicle trafficking assays. Co-administration with mTOR inhibitors enables studies of combinatorial pathway blockade (Vatalis, 2024). Avoid repeated freeze-thaw cycles and long-term storage of diluted solutions to preserve compound integrity.

Conclusion & Outlook

SAR405 is a best-in-class, selective ATP-competitive Vps34 inhibitor, providing a precise pharmacological lever for autophagy inhibition and vesicle trafficking modulation. Its nanomolar potency and selectivity enable targeted studies of the Vps34 kinase signaling pathway, downstream of AMPK-ULK1 regulation. SAR405’s compatibility with mTOR inhibitors and its robust performance in cellular and disease models make it a foundational tool in cancer and neurodegenerative research. Ongoing work integrating SAR405 with advanced cellular readouts and genetic models will further clarify the relationship between energy stress, vesicle trafficking, and autophagy control. For ordering and technical details, refer to the SAR405 product page (SKU: A8883).